Overview

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Please see Terms of Use for this website.

E-mail Alerts

Sign up here to receive press releases via email.

Receive E-mail AlertsE-mail Alerts
Keyword Search
 
2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
May 15, 2013Cell Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences.  UBS Global Healthcare Conference Tuesday, May 21, 2013 at 2:30 p.m. Eastern Time in New York, NY Jefferies 2013 Global Healthcare Conference Tuesday, June 4, 2013 at 3:00 p.m. Eastern Time in New York, NY The presentations will also be webcast live and available for replay after the presentation.  Th... 
Printer Friendly Version
May 02, 2013Cell Therapeutics Reports First Quarter 2013 Financial Results
- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, May 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI® in countries in the European Union where there is market access pending the completion of the reimbursement process," said James Bianco, M.D., President and CEO of CTI. "Although it is ear... 
Printer Friendly Version
Apr 24, 2013Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
- Conference call and webcast at 4:30 p.m. Eastern Time - SEATTLE, April 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter financial results on Thursday, May 2, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET (1:30 p... 
Printer Friendly Version
Apr 10, 2013Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)
SEATTLE, April 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL).  The draft guidance does not recommend fu... 
Printer Friendly Version
Mar 28, 2013Cell Therapeutics Secures $15 Million Loan Financing Agreement
SEATTLE, March 28, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) providing for a senior secured term loan of up to $15 million. "The proceeds from this loan facility are expected to provide us with additional operating capital to advance our Phase 3 clinical development programs," said James A. Bianco, M.D., President and CEO of CTI.  "Our primary focus ... 
Printer Friendly Version
Mar 11, 2013Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
SEATTLE, March 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the ROTH Capital Partners 25th Annual Growth Stock Conference on Monday, March 18, at 2:30 p.m. Pacific/ 5:30 p.m. Eastern/ 10:30 p.m. Central European time at the Ritz-Carlton Laguna Niguel in Dana Point, CA.  The presentation will also be webcast live and available for replay after the presentation.  The webcast can be accessed at www.celltherapeu... 
Printer Friendly Version
Mar 04, 2013Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
SEATTLE, March 4, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). Tosedostat is an oral aminopeptidase inhibitor which has been shown to deprive tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival. The lead ... 
Printer Friendly Version
Mar 01, 2013German Institute for Quality and Efficiency in Health Care (IQWiG) Publishes Dossier Evaluation within Early Benefit Assessment Process of PIXUVRI® (pixantrone)
SEATTLE, March 1, 2013-Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the private German Institute for Quality and Efficiency in Health Care (IQWiG) has published its report on the preliminary benefit assessment of PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In May 2012, the European Commission (EC) granted conditional marketing authorization for PIXUV... 
Printer Friendly Version
Feb 28, 2013Cell Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, Feb. 28, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2012. "During the fourth quarter 2012, we began making PIXUVRI available to healthcare providers in the European Union and initiated commercial operations on a country-by-country basis," said James Bianco, M.D., President and CEO of CTI. "PIXUVRI i... 
Printer Friendly Version
Feb 26, 2013Cell Therapeutics to Report Fourth Quarter and Full Year 2012 Financial Results After Market on February 28, 2013
- Conference call and webcast at 4:30 p.m. Eastern Time - SEATTLE, Feb. 26, 2013 /PRNewswire/ -- Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2012 financial results on Thursday, February 28, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. E... 
Printer Friendly Version
Jan 31, 2013Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
First Planned Interim Survival Analysis Passes Futility Boundary SEATTLE, Jan. 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival ana... 
Printer Friendly Version
Jan 16, 2013Cell Therapeutics to Host Analyst and Investor Meeting on Advances and Existing Challenges in the Treatment of Myelofibrosis with Live Webcast
SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that CTI will provide a live audio and slide webcast of its analyst and investor meeting to be held on January 23 in New York.  Expert speakers will focus on advances in treatment using JAK inhibitors and existing challenges in treating myelofibrosis patients. Guest speakers include: Ross L. Levine, M.D., Associate Member at Memorial Sloan-Kettering Cancer Center in the Human Oncolo... 
Printer Friendly Version
Jan 09, 2013Cell Therapeutics Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib for the Treatment of Myelofibrosis
SEATTLE, Jan. 9, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.  The randomized trial is expected to enroll 270 patients and will evaluate the safety and efficacy of pacritinib compare... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue